Clinical and genetic features of patients with multiple anterior pituitary hormone deficiency caused by mutations in the PROP1 gene; the efficacy of recombinant growth hormone therapy

Rationale. One of the most common causes of multiple anterior pituitary hormone deficiency (MPHD) is genetic defects in the PROP1 gene. PROP1 deficiency leads to malfunction of somatotrophs, lactotrophs, thyrotrophs, corticotrophs, and gonadotrophs. Now, there is an opportunity to conduct large-scale population studies of patients with genetic MPHD, describe their clinical and genetic heterogeneity, and evaluate the efficacy of long-term therapy of these patients with a recombinant growth hormone (rGH).

Aim. The study aim was to assess the spectrum of PROP1 gene mutations in the Russian population of MPHD patients, rate and expected age of hypopituitarism components, and efficacy of rGH therapy.

Material and methods. We analyzed the data of 27 patients diagnosed with MPHD and genetically confirmed mutations in the PROP1 gene who were treated at the Institute of Pediatric Endocrinology of the Endocrinology Research Center (ERC) in 1978―2016. MPHD was diagnosed based on laboratory data and stimulatory tests characterizing the functional activity of the pituitary gland. The molecular genetic study was performed using high-performance parallel sequencing. We used a custom Ampliseq_HP primer panel developed at the Department of Hereditary Endocrinopathies of the ERC, which included coding regions of the following genes: ARNT2, GH1, GHRH, GHRHR, GHSR, GLI2, HESX1, LHX3, LHX4, OTX2, PAX6, POU1F1, PROP1, SHH, SOX2, and SOX3. All patients received rGH therapy at a growth-stimulating dose from the time of GH deficiency diagnosis until final height completion. We evaluated the efficacy of therapy by comparing the achieved final height with the genetically expected one.

Results. Non-familial cases prevailed (N=23) in the study cohort of patients with MPHD caused by mutations in the PROP1 gene; only two patients were monochorionic twin sisters; the other two patients were siblings. An analysis of the distribution of PROP1 gene mutations revealed a hot-point mutation c.301_302delAG in 24 patients (89%, 95% CI 71%; 98%). A mutation in the c.150delA locus occurred in 11 patients (41%, 95% CI 22%; 61%). Two patients had other mutations (c.629delC and c.43_49delGGGCGAG). Total GH deficiency was detected in all patients. The rate of secondary hypothyroidism (SHT) in patients of the study sample was 78% (95% CI 58%; 91%) at the time of diagnosis of GH deficiency and 100% (95% CI 81%; 100%) at the time of final height. The rate of secondary hypogonadism (SHG) at the time of final height was 100% (95% CI 81%; 100%), and the rate of secondary hypocorticism (SHC) was 41% (95% CI 22%; 61%). The normal level of prolactin was detected in 83% (95% CI 65%; 94%) of patients. At the time of growth plate closure, patients receiving rGH therapy at the growth-stimulating dose achieved the genetically expected final height.

Conclusion. According to our findings, the most common mutation in the PROP1 gene is a deletion of AG nucleotides in the 101 codon (c.301_302 delAG), which is found in 89% (95% CI 71%; 98) patients. Patients with MPHD caused by mutations in the PROP1 gene have total GH deficiency and are diagnosed with secondary hypothyroidism and secondary hypogonadism in 100% of cases. The possibility of delayed manifestation of hypopituitarism components requires regular screening of tropic hormone levels for the timely start of substitution therapy and prevention of life-threatening conditions. rGH therapy is highly effective for GH deficiency caused by PROP1 gene mutations and allows patients to achieve the genetically expected height in the case of early diagnosis of growth hormone deficiency.

multiple anterior pituitary hormone deficiency (MPHD) , gene PROP1 , GH deficiency , recombinant growth hormone (rGH)

1. Дедов И.И., Петеркова В.А., Нагаева Е.В. Гормон роста в современной клинической практике. // Лечащий врач. — 2007. — №2. — С. 13—15. [Dedov II, Peterkova VA, Nagaeva EV. Gormon rosta v sovremennoy klinicheskoy praktike.Lechashchiy vrach. 2007;(2):13-15. (шт Russ.)]

2. Pfäffle R, Blum WF. Understanding the Genetics of Growth Hormone Deficiency: A Reference Guide: TMG Healthcare Communications; 2000.

3. Dattani MT. Growth hormone deficiency and combined pituitary hormone deficiency: does the genotype matter? Clin Endocrinol (Oxf). 2005;63(2):121-130. doi: 10.1111/j.1365-2265.2005.02289.x.

4. Петеркова В.А., Фофанова О.В., Тюльпаков А.Н. и др. Диагностика и лечение соматотропной недостаточности у детей. Национальный Консенсус. — М.; 2005. [Peterkova VA, Fofanova OV, Tyulpakov AN, et al. Diagnostika i lechenie somatotropnoy nedostatochnosti u detey. National consensus. Mowcow; 2005. (in Russ.)]

5. Sornson MW, Wu W, Dasen JS et al. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature. 1996;384(6607):327-333. doi: 10.1038/384327a0.

6. Duquesnoy P, Roy A, Dastot F et al. Human Prop-1: cloning, mapping, genomic structure. FEBS Lett. 1998;437(3):216-220. doi: 10.1016/s0014-5793(98)01234-4.

7. Parks JS. Heritable Disorders of Pituitary Development. J Clin Endocrinol Metab. 1999;84(12):4362-4370.doi: 10.1210/jc.84.12.4362.

8. Phelps CJ, Hurley DL. Pituitary Hormones as Neurotrophic Signals: Update on Hypothalamic Differentiation in Genetic Models of Altered Feedback2. Proc Soc Exp Biol Med. 1999;222(1):39-58. doi: 10.1111/j.1525-1373.1999.09994.x.

9. Gage PJ. Ames dwarf mice exhibit somatotrope commitment but lack growth hormone-releasing factor response.Endocrinology. 1995;136(3):1161-1167. doi: 10.1210/en.136.3.1161.

10. Parks JS, Tenore A, Bongiovanni AM, Kirkland RT. Familial Hypopituitarism with Large Sella Turcica. N Engl J Med. 1978;298(13):698-702. doi: 10.1056/nejm197803302981302.

11. Pernasetti F. Impaired Adrenocorticotropin-Adrenal Axis in Combined Pituitary Hormone Deficiency Caused by a Two-Base Pair Deletion (301-302delAG) in the Prophet of Pit-1 Gene. J Clin Endocrinol Metab. 2000;85(1):390-397. doi: 10.1210/jc.85.1.390.

12. Rosenbloom AL. Clinical and Biochemical Phenotype of Familial Anterior Hypopituitarism from Mutation of the PROP1 Gene. J Clin Endocrinol Metab. 1999;84(1):50-57. doi: 10.1210/jc.84.1.50.

13. Пятушкина Г.А. Полиморфизм гена рецептора гормона роста и эффективность рекомбинантных препаратов гормона роста. // Вопросы практической педиатрии. — 2007. — Т. 2. — №5. — С. 12—17. [Pyatushkina GA. Polimorfizm gena retseptora gormona rosta i effektivnost’ rekombinantnykh preparatov gormona rosta. Problems of practical pediatrics. 2007;2(5):12-17. (in Russ.)]

14. Fujieda K, Hanew K, Hirano T et al. Growth response to growth hormone therapy in patients with different degrees of growth hormone deficiency. Endocr J. 1996;43 Suppl:S19-25.

15. Hartmann K, Ittner J, Muller-Rossberg E et al. Growth hormone treatment adherence in prepubertal and pubertal children with different growth disorders. Horm Res Paediatr. 2013;80(1):1-5. doi: 10.1159/000351800.

16. Rocha MG, Marchisotti FG, Osorio MG et al. High prevalence of pituitary magnetic resonance abnormalities and gene mutations in a cohort of Brazilian children with growth hormone deficiency and response to treatment. J Pediatr Endocrinol Metab. 2008;21(7):673-680. doi: 10.1515/jpem.2008.21.7.673

17. Mendonca BB, Osorio MG, Latronico AC et al. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab. 1999;84(3):942-945. doi: 10.1210/jcem.84.3.5537.

18. Lee JK, Zhu YS, Cordero JJ et al. Long-term growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP-1 gene mutation. J Clin Endocrinol Metab. 2004;89(10):4850-4856. doi: 10.1210/jc.2003-031816.

19. Deladoey J, Fluck C, Buyukgebiz A et al. «Hot spot» in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab. 1999;84(5):1645-1650. doi: 10.1210/jcem.84.5.5681.

20. Чикулаева О.А. Молекулярно-генетические, гормональные и иммунологические особенности врожденной соматотропной недостаточности у детей: Дисс. … канд.мед.наук. — М.; 2005. [Chikulaeva OA. Molekulyarno-geneticheskie, gormonal’nye i immunologicheskie osobennosti vrozhdennoy somatotropnoy nedostatochnosti u detey [Dissertation]. Moscow; 2005. (in Russ.)]

21. Mendonca BB, Osorio MG, Latronico AC et al. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab. 1999;84(3):942-945. doi: 10.1210/jcem.84.3.5537.

22. Parks JS, Brown MR, Baumbach L et al. Natural history and molecular mechanisms of hypopituitarism with large sella turcica. In: Book of Abstracts of the 80th Annual Meeting of The Endocrine Society. 1998; 4:471.

23. Cogan JD, WW, Phillips JA et al. The PROP1 2-Base Pair Deletion Is a Common Cause of Combined Pituitary Hormone Deficiency. J Clin Endocrinol Metab. 1998;83(9):3346-3349. doi: 10.1210/jc.83.9.3346.

24. Fofanova OV, Takamura N, Kinoshita E et al. A mutational hot spot in the Prop-1 gene in Russian children with combined pituitary hormone deficiency. Pituitary. 1998;1(1):45-49.

25. Bottner A, Keller E, Kratzsch J et al. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudinal analysis. J Clin Endocrinol Metab. 2004;89(10):5256-5265. doi: 10.1210/jc.2004-0661.

26. Lebl J, Vosahlo J, Pfaeffle RW et al. Auxological and endocrine phenotype in a population-based cohort of patients with PROP1 gene defects. Eur J Endocrinol. 2005;153(3):389-396. doi: 10.1530/eje.1.01989.